Filter News

Caliper Life Sciences, Inc. Continues Momentum With Expanded LabChip 3000 Sales At Top Pharma And Biotech Companies

Published: May 25, 2006

HOPKINTON, Mass., May 25 /PRNewswire-FirstCall/ -- Caliper Life Sciences, Inc. today announced expanded sales of its LabChip(R) 3000 drug discovery system with top tier customers including AstraZeneca, Novartis and Vertex Pharmaceuticals. The LabChip 3000 improves drug discovery and development by employing microfluidic technology, which enables researchers to generate screening and profiling data that reduces artifacts, enhances understanding of biological interactions and ultimately helps scientists better predict which compounds will be successful drug candidates.

The sensitivity and reproducibility of microfluidic experimentation reduces false positives and false negatives, and empowers researchers with analytical quality data that allows them to detect subtle interactions between drug candidates and therapeutic targets. In addition, the LabChip 3000 simplifies drug discovery by enabling a broad range of enzymatic and cellular assays on a single integrated platform. Currently 12 of the top 15 pharmaceutical companies actively use Caliper systems as key tools in their discovery efforts.

"Our customers demand products that accelerate drug discovery and development by providing the most accurate and reliable experimentation results. Increasingly, the pharmaceutical and biotech industries are recognizing the LabChip 3000's ability to deliver those results," said Kevin Hrusovsky, CEO, Caliper Life Sciences. "Sales of LabChip systems have grown rapidly over the past couple of years, to the point that this product line drove our strong organic growth in the first quarter of this year. Continued wins with existing and new customers illustrate the positive industry traction we are seeing in our microfluidics business."

About Caliper Life Sciences

Caliper Life Sciences is a leading provider of drug discovery and life sciences research solutions for the pharmaceutical and biotechnology industries. Caliper's mission is to transform drug discovery and diagnostics by offering a comprehensive array of products and services for clinically relevant experimentation. Based in Hopkinton, Massachusetts, Caliper services approximately 80 percent of the world's leading pharmaceutical companies through representation in 30 countries. More information about Caliper and its products and services can be found on the web at www.caliperLS.com.

The statements in this press release regarding customer demand for our products, expected revenue growth, and industry traction for our microfluidics business are "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statement as a result of a number of factors, including the risk that unexpected difficulties may be encountered in gaining wider adoption of Caliper's microfluidics products, and that Caliper's expectations regarding demand for its products and services may not materialize if capital spending by Caliper's customers declines, if competitors introduce new competitive products, or if Caliper is unable to convince potential customers regarding the superior performance of its LabChip 3000 drug discovery system and other products. Further information on risks faced by Caliper are detailed under the caption "Factors Affecting Operating Results" in Caliper's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 14, 2006. This filing is available on a web site maintained by the Securities and Exchange Commission at http://www.sec.gov. Caliper does not undertake any obligation to update forward-looking or other statements in this release or the conference call.

NOTE: LabChip and Caliper are registered trademarks of Caliper Life Sciences, Inc.

Caliper Life Sciences, Inc.

CONTACT: Michele Boudreau, Corporate Communications of Caliper LifeSciences, Inc., +1-650-279-2088; or Stacey Holifield of SchwartzCommunications, +1-781-684-0770, or caliper@schwartz-pr.com, for CaliperLife Sciences, Inc.

Back to news